Items | Odds | 95% CI | χ2 | p Value |
---|---|---|---|---|
(A) Univariate logistic regression analysis | ||||
Age (years) | 0.955 | 0.907 to 1.007 | 2.942 | 0.0863 |
Duration, disease (years) | 0.964 | 0.908 to 1.025 | 1.379 | 0.2403 |
ADA admin periods (weeks) | 0.978 | 0.956 to 1.000 | 3.82 | 0.0507 |
DAS28-4ESR | 0.094 | 0.020 to 0.438 | 9.07 | 0.0026** |
RF (U/mL) | 1.011 | 0.998 to 1.025 | 2.884 | 0.0895 |
(B) Multivariate logistic regression analysis | ||||
Age (years) | 0.963 | 0.963 to 0.906 | 1.441 | 0.2300 |
ADA admin periods (weeks) | 0.985 | 0.985 to 0.959 | 1.254 | 0.2629 |
DAS28-4ESR | 0.143 | 0.143 to 0.029 | 5.653 | 0.0174** |
RF (U/mL) | 1.012 | 1.012 to 0.996 | 2.127 | 0.1448 |
Univariate logistic regression analysis was performed using items with p<0.1 in table 2 to investigate factors related to sustained remission for 1 year after ADA discontinuation. Then, multivariate analyses were conducted using the variables with p<0.2 in the univariate analysis. Using the DAS28-4ESR values which were significant in logistic analysis, ROC analysis was conducted with the response (dependent) variable of if DAS28-4ESR <2.6 (1) or ≥2.6 (0) 1 year after discontinuation of ADA and the explanatory variable of DAS28-4ESR at the timing of ADA discontinuation. **p<0.01: Wald test.
ADA administration periods, adalimumab administration periods; DAS28, disease activity score 28; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.